BioSpace News Archive

The conference will be held from March 7-10 in Miami.

Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™.

Data from its First Pediatric Study are Anticipated in the Second Half of 2019

- -Designed for Rapid Basic Metabolic Testing in Emergency Departments and Other Hospital Point-of-Care Settings- -

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, March 18, 2019.

Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration

Givosiran Meets Primary and Majority of Secondary Endpoints, with Significant Reduction in Annualized Rate of Composite Porphyria Attacks Relative to Placebo

Conference Call Scheduled for Wednesday, March 13 at 4:30 p.m. Eastern Time

Pharm-Olam is marking its 25th anniversary with several announcements.